Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3

Melanoma and Skin Cancer

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL)

Br J Dermatol

Nardin C, Cavalieri C, Lebbé C, Gérard E, Puyraveau M, Vergara R, Maubec E, Kramkimel N, Lesage C, Rouanet J, Bonniaud B, Puzenat E, Popescu D, Baroudjian B, Le Corre Y, Saiag P, Brunet Possenti F, Saint-Jean M, Montaudié H, Amini-Adle M, Belkaid S, Grange F, Mansard S, Béjar CL, Darras S, Pages C, Tournier E, Funck-Brentano E, Aubin F

doi: 10.1093/bjd/ljaf268

Melanoma and Skin Cancer

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

J Eur Acad Dermatol Venereol

Sanogo D, Levard R, Cassecuel J, Khammari A, Quereux G, Grange F, Montaudié H, Brunet-Possenti F, Lavaud J, Leccia MT, Jeudy G, Dompmartin A, Dreno B, L'Orphelin JM

doi: 10.1111/jdv.70136

Melanoma and Skin Cancer

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg

Eur J Cancer

Zimmermann N, Kött J, Zell T, Abedini AZ, Blomen CL, Belz S, Deitert B, Heidrich I, Geidel G, Rünger A, Smit DJ, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, von Wasielewski I, Mohr P, Meier F, Herbst R, Utikal J, Terheyden P, Haferkamp S, Pföhler C, Kaatz M, Ziller F, Ulrich J, Meiss F, Bauer AT, Schneider SW, Gebhardt C

doi: 10.1016/j.ejca.2025.116195

Melanoma and Skin Cancer

Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study

J Am Acad Dermatol

Schlesinger T, Chapman MS, Tu JH, Cohen JL, Strasswimmer J, Zeitouni NC, Torres A, Jazayeri SS, Goldman MP, Ibrahim SF, Lain EL, Couvillion MP, Bruce S, Laquer VT, Hanke CW, Ozog DM, Schneider J, Markowitz O, Berman B, Nestor MS, Gold MH, Munavalli GS, Forsha DW, Siegel DM, Mrohs D, Schmitz B, Schäning R, Pospiech N, Lyons J, Foguet M, Lübbert M, Lübbert H, Pariser DM

doi: 10.1016/j.jaad.2025.08.031

Melanoma and Skin Cancer

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

J Eur Acad Dermatol Venereol

Schumann K, Klespe KC, Mauch C, Loquai C, Schultheis U, Börger S, Thiem A, Emmert S, Hoellwerth M, Koelbinger P, Nguyen VA, Wanner M, Richtig E, Peitsch WK, Harth W, Zenderowski V, Braun AD, Mengoni M, Dummer R, Mangana J, Maul LV, Meis F, Rappersberger K, Persa OD, Biedermann T, Posch C

doi: 10.1111/jdv.20708

Melanoma and Skin Cancer

Tumor necrosis alpha inhibitor therapy is associated with increased long-term risk of non-melanoma skin cancer and melanoma: a retrospective cohort study

J Am Acad Dermatol

Driscoll CB, Schwab G, Quan VL, McKenney J, Hooper MJ, Shankar Ramesh Kumar SK, Kundu RV, Kundu SD

doi: 10.1016/j.jaad.2026.02.035

Rheumatoid Arthritis

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Rheumatology (Oxford)

Fujii T, Murata K, Nakabo S, Onishi A, Murakami K, Tanaka M, Morinobu A, Matsuda S

doi: 10.1093/rheumatology/keaf598

Melanoma and Skin Cancer

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21

Br J Dermatol

Mistry K, Jeffrey P, Levell NJ, Kennedy O, Richardson K, Craig P, Bright C, Taylor S, Ragan J, Karponis D, Pethick J, Lavelle K, McRonald F, Hardy S, Vernon S, Lorigan P, Venables ZC

doi: 10.1093/bjd/ljaf351

Melanoma and Skin Cancer

Safety of tranexamic acid in patients with stage III melanoma undergoing lymph node dissection: a retrospective cohort study

Melanoma Res

Kristjansen KA, Mensel C, Larsen MØ, Dam-Dalgeir G, Munk KW, Maarouf A, Ikander P, Alstrup T, Guldbrandt LM, Bønnelykke-Behrndtz ML

doi: 10.1097/CMR.0000000000001084

Related content

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL)

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg

Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

Tumor necrosis alpha inhibitor therapy is associated with increased long-term risk of non-melanoma skin cancer and melanoma: a retrospective cohort study

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21

Safety of tranexamic acid in patients with stage III melanoma undergoing lymph node dissection: a retrospective cohort study